基于血水同治理论探讨增殖性玻璃体视网膜病变的治疗  

Treatment of proliferative vitreoretinopathy based on the theory of blood-water co-treatment

作　　者：白海霞 刘晓清 吴权龙[1,2] 彭清华[1,3] BAI Haixia;LIU Xiaoqing;WU Quanlong;PENG Qinghua(Hunan University of Chinese Medicine,Changsha 410208,China)

机构地区：[1]湖南中医药大学,湖南长沙410208 [2]湖南中医药大学第一附属医院,湖南长沙410007 [3]湖南省中医药防治眼耳鼻咽喉疾病与视功能保护工程技术研究中心,湖南长沙410208

出　　处：《陕西中医》2023年第9期1252-1254,1258,共4页Shaanxi Journal of Traditional Chinese Medicine

基　　金：国家自然科学基金资助项目(81804149);中药粉体与创新药物省部共建国家重点实验室培育基地开放基金资助项目(21PTKF1003);湖南省自然科学基金资助面上项目(2022JJ40226);湖南中医药大学“王衡新基金”专项课题(2023HX003)。

摘　　要：增殖性玻璃体视网膜病变是孔源性视网膜脱离和眼球后段穿通伤的严重并发症,由于损伤处过度纤维化使视网膜再脱离,导致视力下降、视物模糊,严重危害视力健康。该病发病率约为5%~10%,目前临床上尚无理想治疗药物,手术治疗虽有效但存在一定风险及复发率。《审视瑶函》记载“血养水,水养膏,膏护瞳神”,血水运化不利,日久形成有形实邪积聚于神膏及视衣之上以致视物不能。基于血水同治理论探讨增殖性玻璃体视网膜病变的治疗具有一定价值,可为中医治疗该病提供理论依据及指导。Proliferative vitreoretinopathy(PVR)is a serious complication of rhegmatogenous retinal detachment and penetrating injury of posterior segment of eyeball.The incidence of this disease is about 5%~10%.Currently,there is no ideal therapeutic drug in clinical practice.Although surgical treatment is effective,there are certain risk and recurrence rate.Shen Shi Yao Han records“blood nourishing water,water nourishing ointment,ointment to protect pupil”,blood and water transport is stagnant,form visible pathogen accumulate in shengao and shiyi for a long time so that it can not see anything.The treatment of proliferative vitreoretinopathy based on the theory of blood-water co-treatment has achieved a good effect,which can provide theoretical basis and guidance for the treatment of PVR in traditional Chinese medicine.

关 键 词：增殖性玻璃体视网膜病变 血水同治 痰瘀互结 视瞻昏渺 活血利水法 散血明目片 

分 类 号：R774.1[医药卫生—眼科]